The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy

Journal of Hepatology

Volumn 48, Issue 5, 2008, Pages 736-742

  Kurosaki, Masayuki ^a   Matsunaga, Kotaro ^a   Hirayama, Itsuko ^a   Tanaka, Tomohiro ^a   Sato, Mitsuaki ^a   Komatsu, Nobutoshi ^a   Umeda, Naoki ^a   Hosokawa, Takanori ^a   Ueda, Ken ^a   Tsuchiya, Kaoru ^a   Nakanishi, Hiroyuki ^a   Itakura, Jun ^a   Asahina, Yasuhiro ^a   Miyake, Shozo ^a   Enomoto, Nobuyuki ^b   Izumi, Namiki ^a  

^a MUSASHINO RED CROSS HOSPITAL   (Japan)

^b UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

ALT; Fibrosis; Steatosis

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERFERON; RIBAVIRIN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FATTY LIVER; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SCORING SYSTEM; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; ALANINE TRANSAMINASE; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; FATTY LIVER; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER CIRRHOSIS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED;

EID: 40949112265     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2007.12.025     Document Type: Article

References (35)

1. Liang T.J., Rehermann B., Seeff L.B., and Hoofnagle J.H. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 132 (2000) 296-305
2. Poynard T., McHutchison J., Davis G.L., Esteban-Mur R., Goodman Z., Bedossa P., et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 32 (2000) 1131-1137
3. Yoshida H., Shiratori Y., Moriyama M., Arakawa Y., Ide T., Sata M., et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 131 (1999) 174-181
4. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V.K., Shiffman M., Reindollar R., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 (2001) 958-965
5. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales Jr. F.L., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 (2002) 975-982
6. Poynard T., Bedossa P., and Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349 (1997) 825-832
7. Marcellin P., Asselah T., and Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology 36 (2002) S47-S56
8. Alberti A., Vario A., Ferrari A., and Pistis R. Review article: chronic hepatitis C - natural history and cofactors. Aliment Pharmacol Ther 22 Suppl 2 (2005) 74-78
9. Lefkowitch J.H., Schiff E.R., Davis G.L., Perrillo R.P., Lindsay K., Bodenheimer Jr. H.C., et al. Pathological diagnosis of chronic hepatitis C: a multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Therapy Group. Gastroenterology 104 (1993) 595-603
10. Hourigan L.F., Macdonald G.A., Purdie D., Whitehall V.H., Shorthouse C., Clouston A., et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 29 (1999) 1215-1219
11. Adinolfi L.E., Gambardella M., Andreana A., Tripodi M.F., Utili R., and Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 33 (2001) 1358-1364
12. Westin J., Nordlinder H., Lagging M., Norkrans G., and Wejstal R. Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. J Hepatol 37 (2002) 837-842
13. Fartoux L., Chazouilleres O., Wendum D., Poupon R., and Serfaty L. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology 41 (2005) 82-87
14. Leandro G., Mangia A., Hui J., Fabris P., Rubbia-Brandt L., Colloredo G., et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 130 (2006) 1636-1642
15. Asselah T., Boyer N., Guimont M.C., Cazals-Hatem D., Tubach F., Nahon K., et al. Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C. Gut 52 (2003) 1638-1643
16. Hui J.M., Sud A., Farrell G.C., Bandara P., Byth K., Kench J.G., et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology 125 (2003) 1695-1704
17. Perumalswami P., Kleiner D.E., Lutchman G., Heller T., Borg B., Park Y., et al. Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. Hepatology 43 (2006) 780-787
18. Conjeevaram H.S., Kleiner D.E., Everhart J.E., Hoofnagle J.H., Zacks S., Afdhal N.H., et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 45 (2007) 80-87
19. Bedossa P., and Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 24 (1996) 289-293
20. Castera L., Hezode C., Roudot-Thoraval F., Bastie A., Zafrani E.S., Pawlotsky J.M., et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 52 (2003) 288-292
21. Mihm S., Fayyazi A., Hartmann H., and Ramadori G. Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology 25 (1997) 735-739
22. Fartoux L., Poujol-Robert A., Guechot J., Wendum D., Poupon R., and Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 54 (2005) 1003-1008
23. Hickman I.J., Clouston A.D., Macdonald G.A., Purdie D.M., Prins J.B., Ash S., et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 51 (2002) 89-94
24. Belfort R., Harrison S.A., Brown K., Darland C., Finch J., Hardies J., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355 (2006) 2297-2307
25. Paradis V., Perlemuter G., Bonvoust F., Dargere D., Parfait B., Vidaud M., et al. High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology 34 (2001) 738-744
26. Day C.P., and James O.F. Steatohepatitis: a tale of two "hits"?. Gastroenterology 114 (1998) 842-845
27. Paradis V., Mathurin P., Kollinger M., Imbert-Bismut F., Charlotte F., Piton A., et al. In situ detection of lipid peroxidation in chronic hepatitis C: correlation with pathological features. J Clin Pathol 50 (1997) 401-406
28. Walsh M.J., Vanags D.M., Clouston A.D., Richardson M.M., Purdie D.M., Jonsson J.R., et al. Steatosis and liver cell apoptosis in chronic hepatitis C: a mechanism for increased liver injury. Hepatology 39 (2004) 1230-1238
29. Mathurin P., Moussalli J., Cadranel J.F., Thibault V., Charlotte F., Dumouchel P., et al. Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 27 (1998) 868-872
30. Ghany M.G., Kleiner D.E., Alter H., Doo E., Khokar F., Promrat K., et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 124 (2003) 97-104
31. Seidel N., Volkmann X., Langer F., Flemming P., Manns M.P., Schulze-Osthoff K., et al. The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum. Hepatology 42 (2005) 113-120
32. Shiffman M.L., Hofmann C.M., Contos M.J., Luketic V.A., Sanyal A.J., Sterling R.K., et al. A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia. Gastroenterology 117 (1999) 1164-1172
33. Omata M., Yoshida H., Toyota J., Tomita E., Nishiguchi S., Hayashi N., et al. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C. Gut 56 (2007) 1747-1753
34. Takano S., Ito Y., Yokosuka O., Ohto M., Uchiumi K., Hirota K., et al. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 20 (1994) 558-564
35. Ortiz V., Berenguer M., Rayon J.M., Carrasco D., and Berenguer J. Contribution of obesity to hepatitis C-related fibrosis progression. Am J Gastroenterol 97 (2002) 2408-2414